McKesson Corp. Reveals Increase In Q4 Profit

McKesson reported Q4 GAAP earnings of $1.68 billion, or $13.78 per share, up from $1.26 billion, or $10.06 per share, a year ago. Revenue rose 6.0% to $96.29 billion from $90.82 billion, and adjusted EPS came in at $11.69. The results indicate solid operating performance for the healthcare distributor, with modestly positive implications for the stock.

Analysis

McKesson’s print is more important for what it says about distribution economics than for the headline beat. The operating leverage here implies the pharmacy/wholesale channel is still benefiting from mix and scale, which tends to pressure smaller distributors and independents that lack purchasing power and working-capital flexibility. If this persists, expect further share consolidation in the channel and stronger negotiating leverage against suppliers, especially in categories where reimbursement lag is short and inventory turns matter.

The second-order winner is not just MCK shareholders but adjacent healthcare services names that ride the same volume engine without taking as much inventory risk. Elevated cash generation also widens the gap between large-cap distributors and the more levered PBM/health-services complex: in a tighter credit environment, balance sheet durability becomes a competitive moat. The main near-term risk is margin normalization if generic pricing, payer mix, or inventory gains mean-revert over the next 1-2 quarters.

Consensus may be underestimating how much of the improvement is structural rather than cyclical. If management is converting scale into durable incremental margin, the market should treat this as a compounding story rather than a one-quarter earnings event; that usually supports multiple expansion over 6-12 months. The contrarian angle is that strong reported earnings can mask slower underlying unit growth, so any disappointment in volume, reimbursement, or acquisition cadence could reverse sentiment quickly even if headline EPS remains elevated.

Key Decisions for Investors

• Stay long MCK into the next 1-3 months, but use pullbacks rather than chasing strength; the setup is favorable if execution remains clean and the market re-rates the durability of cash flow.
• Pair long MCK vs. short a smaller healthcare distributor or services name with weaker scale and leverage; the thesis is that operating leverage and purchasing power should widen the spread over 3-6 months.
• If already long, buy downside protection via MCK puts 2-4 months out around the next earnings window; the key risk is a rapid margin giveback that the market may punish disproportionately.
• Look for confirmation in other healthcare distribution names over the next quarter; if peers do not show similar margin resilience, treat MCK as the preferred relative-value long in the group.